Amgen Inc. (AMGN) Q2 2014 Earnings Results

Amgen Beats on EPS, Stock Up 0.54%

Amgen's strong EPS performance indicates better-than-expected profitability, which likely contributed to the slight increase in stock price. However, the lack of revenue data and guidance may leave investors cautious. The stock's modest rise suggests that while investors are pleased with the earnings beat, they are also looking for more clarity on future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$2.37	N/A	+19.28%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in the company's current trajectory while remaining cautious about market conditions.

Management highlighted strong performance in key therapeutic areas.

They emphasized ongoing investments in research and development.

Amgen Beats on EPS, Stock Up 0.54%

Key numbers

Management commentary

Amgen Inc.

More earnings this week

Amgen Beats on EPS, Stock Up 0.54%

Key numbers

Management commentary